(Reuters) – The U.S. government on Tuesday selected the first 10 drugs, including the big-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer, that will be subject to the first-ever Medicare price negotiations, part of President Joe Biden’s Inflation Reduction Act (IRA) that drugmakers and industry groups have challenged in court.
At least eight lawsuits were filed between June and late August seeking to block the price negotiation, arguing that the law and forced price cuts would violate various amendments to the U.S. constitution. The following are key details of the lawsuits:
Company Date Location Drugs named
filed in lawsuit
as likely to
be affected
by IRA
Merck & Co June 6 U.S. District Court Diabetes
for the District of drugs
Columbia Januvia and
Janumet,
cancer
treatment
Keytruda
The U.S. June 9 U.S. District Court NA
Chamber of for the Southern
Commerce District Of Ohio
Western Division
Bristol Myers June 16 U.S. District Court Blood
Squibb for the District of thinner
New Jersey Eliquis,
cancer
therapy
Opdivo
Astellas July 14 U.S. District Court Prostate
Pharma For The Northern cancer drug
District of Illinois, Xtandi,
Eastern Division Myrbetriq
for treating
overactive
bladder
Johnson & July 18 U.S. District Court Blood
Johnson for the District of thinner
New Jersey Xarelto
Pharmaceutica June 21 U.S. District Court NA
l Research For the Western
and District Of Texas
Manufacturers Austin Division
of America
Boehringer Aug 18 U.S. District Court Diabetes
Ingelheim for the District Of drug
Connecticut Jardiance
AstraZeneca Aug 25 U.S. District Court Cancer drug
For the District Of Lynparza,
Delaware blood
disorder
treatment
Soliris
(Reporting by Manas Mishra and Sriparna Roy in Bengaluru; Editing by Bill Berkrot)
